15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Candel Therapeutics Inc, 8 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $7.00 to $26.00 (about 3.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $19.14 sits 98% above the current $9.68. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-0.60 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy889%
Hold111%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Candel Therapeutics Inc.
As of Jul, 8 of 9 firms rate CADL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CADL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.26 – $-0.24 · 2 analysts · +11% YoY
Next period, 2 analysts expect Candel Therapeutics Inc to earn $-0.25 a share (range $-0.26 – $-0.24), versus $-0.23 a year earlier. Full-year consensus is $-0.90, growing to $-0.60 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $42.8M next year.
Top analysts covering Candel Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CADL.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$23.00+137.6% to target
Overall win rate
46%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$26.00+168.6% to target
Overall win rate
43%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$23.00+137.6% to target
Overall win rate
38%
+ Follow
#4
John Newman
Canaccord Genuity · Rank #340
Buy
$25.00+158.3% to target
Overall win rate
30%
+ Follow
#5
Vernon Bernardino
HC Wainwright & Co. · Rank #379
Buy
$19.00+96.3% to target
Overall win rate
14%
+ Follow
CADL stock forecast FAQ
What is CADL's average 12-month price target?+
The 6 analysts with a live target average $19.14 for Candel Therapeutics Inc over the next 12 months, ranging from a $26.00 high to a $7.00 low.
Is CADL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 8 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CADL?+
The Street-high target is $26.00 (Citigroup), and the Street-low is $7.00 (B of A Securities). The average of all 6 active targets is $19.14.
How many Wall Street analysts cover CADL?+
9 analysts have an active rating on Candel Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CADL?+
Among analysts who currently cover CADL, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $23.00 target.
What is Candel Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.26 – $-0.24) across 2 analysts. Full-year EPS is projected at $-0.90, rising to $-0.60 the following year.
How much revenue is Candel Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $42.8M next year.
Have analysts been upgrading or downgrading CADL lately?+
As of Jul, 8 of 9 firms rate CADL a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CADL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
